XBIT XBiotech Inc

Price (delayed)

$7.06

Market cap

$215.07M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.16

Enterprise value

$36.54M

XBiotech is a fully integrated, global biopharmaceutical company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies. XBiotech currently is advancing a pipeline of therapies by harnessing naturally ...

Highlights
XBIT's revenue has dropped by 100% year-on-year
XBIT's gross profit has dropped by 100% year-on-year

Key stats

What are the main financial stats of XBIT
Market
Shares outstanding
30.46M
Market cap
$215.07M
Enterprise value
$36.54M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.09
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$34.8M
EBITDA
-$33.07M
Free cash flow
-$24.53M
Per share
EPS
-$1.16
Free cash flow per share
-$0.81
Book value per share
$6.46
Revenue per share
$0
TBVPS
$7.08
Balance sheet
Total assets
$215.56M
Total liabilities
$18.85M
Debt
$10M
Equity
$196.7M
Working capital
$173.5M
Liquidity
Debt to equity
0.05
Current ratio
11.13
Quick ratio
11
Net debt/EBITDA
5.4
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-15.6%
Return on equity
-16.5%
Return on invested capital
-168.9%
Return on capital employed
-17.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

XBIT stock price

How has the XBiotech stock price performed over time
Intraday
0%
1 week
5.85%
1 month
16.31%
1 year
55.16%
YTD
76.5%
QTD
37.35%

Financial performance

How have XBiotech's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$42.93M
Net income
-$35.01M
Gross margin
N/A
Net margin
N/A
XBIT's revenue has dropped by 100% year-on-year
XBIT's gross profit has dropped by 100% year-on-year
XBiotech's net income has decreased by 23% YoY and by 14% from the previous quarter
The company's operating income fell by 23% YoY and by 4.1% QoQ

Growth

What is XBiotech's growth rate over time

Valuation

What is XBiotech stock price valuation
P/E
N/A
P/B
1.09
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
XBiotech's EPS has decreased by 23% YoY and by 14% QoQ
The P/B is 36% higher than the last 4 quarters average of 0.8 but 16% lower than the 5-year quarterly average of 1.3
The equity has declined by 14% year-on-year and by 6% since the previous quarter
XBIT's revenue has dropped by 100% year-on-year

Efficiency

How efficient is XBiotech business performance
XBIT's ROIC has shrunk by 108% QoQ
The return on equity has declined by 38% year-on-year and by 18% since the previous quarter
XBIT's ROA is down by 33% YoY and by 16% QoQ

Dividends

What is XBIT's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history

Special dividends are included in TTM DPS and yield

Financial health

How did XBiotech financials performed over time
The current ratio has plunged by 76% YoY and by 7% from the previous quarter
XBIT's quick ratio has dropped by 76% year-on-year and by 8% since the previous quarter
The debt is 95% lower than the equity
The equity has declined by 14% year-on-year and by 6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.